Trade Ideas

Actionable trade ideas with defined risk and time horizons.

Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.

Articles

10,764 total articles

Buy CytomX (CTMX) on Varseta-M Momentum and a Comfortable Cash Runway

Buy CytomX (CTMX) on Varseta-M Momentum and a Comfortable Cash Runway

CytomX (CTMX) is a clinical-stage oncology biotech advancing varsetatug masetecan (Varseta-M) with upside driven by clinical progress and partnership milestones. A $250M equity raise in March 2026 and a June expansion of the Regeneron collaboration meaningfully reduce near-term dilution risk and extend runway, creating a favorable risk-reward for a…

Greggs: Buy a Reliable Growth Story at a Reasonable Price

Greggs: Buy a Reliable Growth Story at a Reasonable Price

Greggs is a resilient, cash-generative UK bakery chain trading at a valuation that looks fair but not demanding. A disciplined long entry here balances upside from execution and new product momentum against macro and commodity risks. Trade plan: enter at $25.00, target $30.00, stop $21.00 — horizon: long term (180 trading days).

908 Devices (MASS) - Tactical Long on Mission-Critical Mass Spectrometry

908 Devices (MASS) - Tactical Long on Mission-Critical Mass Spectrometry

908 Devices makes small, mission-critical mass spectrometers used by customs, food labs, and biotech clients. Recent contract wins and steady top-line growth (Q2 2025 revenue $13.0M, +14% YoY) alongside a manageable enterprise value (~$346M) support a tactical long. Expect near-term volatility; plan for a defined entry, stop and target over a 180 t…

Astera Labs: Ride the AI Fabric Inflection — A Tactical Long Setup

Astera Labs: Ride the AI Fabric Inflection — A Tactical Long Setup

Astera Labs is trading on momentum after AWS' AI strength and the company’s own accelerating revenue and cash generation. With profitable margins, a debt-free balance sheet and improving technicals, ALAB offers an asymmetric risk/reward for a disciplined swing trade. Entry $332.63, stop $305.00, target $420.00 — mid-term horizon (45 trading days).

CECO Environmental: Execution Paying Off — Time to Add on Strength

CECO Environmental: Execution Paying Off — Time to Add on Strength

CECO Environmental (CECO) has delivered on the two biggest near-term items investors were watching: a strengthened orders outlook and a strategic merger with Thermon that adds scale and cross-selling opportunity. Fundamentals remain mixed — high valuation and modest free cash flow — but the combination, order growth target (> $1.5B), and improving …

Small Scanner, Big Ambition - Why BFLY Is Worth a Conditional Long

Small Scanner, Big Ambition - Why BFLY Is Worth a Conditional Long

Butterfly Network has moved from gadget to platform: a $2.95B market cap, strong balance-sheet ratios, and accelerating adoption of AI-enabled point-of-care imaging support a long trade. Entry at $9.22 with a $13.00 target and $7.50 stop, held over a 120 trading-day horizon, balances upside from software/recurring revenue with the valuation and ins…

eToro: Oversold Setup with Profitable Ops — A Mid-Term Long Idea

eToro: Oversold Setup with Profitable Ops — A Mid-Term Long Idea

eToro's trading activity has cooled — smaller check sizes and weaker crypto flows — yet the stock trades at a modest multiple with profitable operations, a $150M buyback in the background, and acquisition-driven crypto capability expansion. Technicals are deeply oversold, creating an asymmetric mid-term trade if you size risk carefully.

Palantir: Buy the AI Franchise After an 'Otherworldly' Q2 — Target $220 Over the Next 180 Trading Days

Palantir: Buy the AI Franchise After an 'Otherworldly' Q2 — Target $220 Over the Next 180 Trading Days

Palantir posted a Q2 that rewrites the AI playbook for large-enterprise software: 93% revenue growth, U.S. commercial up 149%, and a 55% net margin. That operating strength and raised guidance justify a long-term buy thesis, but the stock already prices in years of rapid execution. I outline a disciplined entry at $165.00, a $145 stop, and a $220 t…

Lumentum Is Overpriced for Perfection - Fade the Post-Quarter Euphoria

Lumentum Is Overpriced for Perfection - Fade the Post-Quarter Euphoria

Lumentum (LITE) trades at nosebleed multiples - PE ~145, EV/EBITDA ~103, and price-to-free-cash-flow ~560x - pricing flawless execution and sustained hypergrowth. Recent earnings and guidance (market reaction) suggest demand variability and margin sensitivity; that combination creates a high-reward trade to fade optimism. Short at $945.41, stop $1,…